Institut Paoli-calmettes
Clinical trials sponsored by Institut Paoli-calmettes, explained in plain language.
-
New hope for tough leukemia: DASATINIB trial targets resistant cases
Disease control Recruiting nowThis study tests a drug called DASATINIB in people with acute myeloid leukemia (AML) whose cancer did not improve after standard treatment with VENETOCLAX and AZACITIDINE. About 35 adults who cannot have strong chemotherapy will take DASATINIB for up to 3 months. Researchers will…
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Leukemia treatment breakthrough: could less be more for responding patients?
Disease control Recruiting nowThis study tests whether adults with acute myeloid leukemia (AML) who have responded well to a year of venetoclax and azacitidine can safely stop these drugs. Fifty participants will discontinue treatment and be closely monitored for relapse. The goal is to see if stopping therap…
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC